PapersPMID:38167633
Acanthopanax senticosus ameliorates steatohepatitis through HNF4 alpha pathway activation in mice.
What moved
1 findingHow to read these marks →- Decreases alanine aminotransferase
insufficient
“In contrast, HFA administration significantly decreased ALT levels, and the liver lipids of TG and cholesterol in HFA-fed mice decreased more than in HF-fed mice.”
- Study
- animal · not in humans
- Duration
- 6 weeks
- Interests
- Industry funded
- Dose studied
- 5% ASHE mixed into the high-fat diet, ad libitum, for 6 weeks
- Population
- Male C57BL/6J mice fed a choline-deficient, L-amino acid-defined, high-fat diet for 6 weeks (steatohepatitis model); the same diet with 5% Acanthopanax senticosus Harms extract against that diet alone; serum ALT measured by a commercial laboratory
Study record
- Design
- animal study, in vivo
- Species
- animal / mixed
- Population
- Male C57BL/6J mice (10 weeks old at the experiment) on a choline-deficient, L-amino acid-defined high-fat diet (steatohepatitis model); plus palmitate-treated HepG2 cells
- Participants
- 18
- Comparator
- no treatment / placebo
- Duration
- 42 days
- Endpoints measured
- 27